What is Option Care's gross profit margin?

What is Option Care's latest dividend and current dividend yield?

What guidance did Option Care's management provide for the next earnings period?

What does Option Care do and what are its main business segments?

Did Option Care beat or miss consensus estimates last quarter?

What were the key takeaways from Option Care’s earnings call?

What is the revenue and EPS growth rate for Option Care year over year?

What is the market's earnings forecast for Option Care next quarter?

- **Revenue Momentum**: 12% YoY growth driven by acute therapy gains and chronic portfolio expansion, despite Stelara biosimilar headwinds.
- **Strategic Investments**: Advanced practitioner model expanded to 24 locations; 3 new tech apps launched to enhance efficiency.
- **Financial Strength**: Raised full year guidance to $5.6B-$5.65B revenue, $1.68-$1.72 EPS, supported by $223M cash flow generation.
- **Risk Management**: 2025 Stelara impact capped at $70M, but 2026 biosimilar uptake and new therapy launches pose uncertainty.
- **Capital Allocation**: Prioritizing growth investments (infusion suites, tech) over buybacks, with disciplined M&A approach.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue grew 12% YoY, driven by mid-teens growth in acute therapies and low double-digit growth in chronic therapies. Acute growth benefited from a competitive landscape shift, while chronic growth included new therapies and services.
- **Stelara Biosimilar Impact**: Uptake of Stelara biosimilars reduced gross profit by 380 basis points, with expectations for continued headwinds in 2026. The company is focused on minimizing the impact through portfolio diversification.
- **Strategic Initiatives**: Expanded advanced practitioner model to 24 locations, launched 3 new technology applications for efficiency, and integrated the Intramed Plus acquisition. Infusion suite utilization grew to 34% of nursing visits.
- **Market Positioning**: Emphasized home and alternate site care as cost-effective solutions, with partnerships in bed day management and site of care programs to reduce payer MLR.

**【CFO Financial Commentary】**
- **Financial Performance**: Q3 2025 revenue $1.4B, adjusted EBITDA $119.5M (3.4% YoY growth), adjusted EPS $0.45 (9.8% YoY). Full year guidance raised to $5.6B-$5.65B revenue, $468M-$473M EBITDA, $1.68-$1.72 EPS.
- **Cash Flow & Capital Allocation**: Generated $223M year-to-date cash flow, refinanced debt to reduce costs, and repurchased $62M in shares. Priorities: internal growth investments, M&A tuck-ins, and shareholder returns.
- **Cost Management**: G&A up 10% YoY due to acquisition costs, variable comp normalization, and technology investments. Gross margin pressured by Stelara biosimilar and rare therapy margins.

**【Q&A Highlights】**
- **Stelara Outlook**: 2025 impact $65M-$70M, with Q4 drag similar to Q3. 2026 uncertainty due to biosimilar uptake and new therapy launches (TREMFYA, Skyrizi). No exit plans despite margin compression.
- **M&A Strategy**: Focused on tuck-ins and near adjacencies (e.g., nursing agencies, tech platforms). Private multiples (2x+ EV/EBITDA) justify disciplined approach.
- **Regulatory Environment**: Navigating IRA and MFN pricing risks, with minimal 2025 impact. Long-term focus on value-based care partnerships.
- **Advanced Practitioner Model**: 175 facilities with 24 advanced practitioners, targeting higher acuity patients. Regulatory challenges (e.g., corporate practice of medicine) may slow expansion.
- **Gross Margin Risks**: Biosimilar pricing and rare therapy margins expected to weigh on gross profit, but diversified portfolio mitigates risk.

Option Care Health, Inc. (OPCH) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: 15.4% YoY driven by mid-teens acute and chronic therapy growth, offsetting $20 million Stelara impact.
- **Margin Expansion**: 5.2% EBITDA growth to $114 million, with 35% of nursing visits in suites boosting efficiency.
- **Share Buybacks**: $50 million in Q2, with >$320 million annual cash flow supporting capital returns.
- **Clinical Innovation**: Advanced practitioner model expands to 170 facilities, targeting oncology and Alzheimer's patients.
- **Tariff Resilience**: No material 2025 impact expected; proactive inventory and pharma strategies mitigate risks.

**【CEO Opening Remarks】**
- **Revenue Growth**: Q2 revenue increased 15.4% YoY, driven by mid-teens growth in both acute and chronic therapies. Acute therapy growth outpaced the overall market, while chronic therapies saw strong performance in rare and orphan drugs.
- **EBITDA Expansion**: Adjusted EBITDA rose 5.2% YoY to $114 million, despite headwinds from lower-margin therapies. Management expects continued margin improvement through operational efficiency and suite utilization.
- **Capital Deployment**: $50 million in share repurchases during Q2, with plans to balance M&A, internal investments, and shareholder returns. Cash flow from operations exceeded $90 million in Q2, supporting full-year guidance of >$320 million.
- **Clinical Model Innovation**: Advanced practitioner model expanded to serve higher acuity patients, with 170 facilities and 750 chairs enabling 35% of nursing visits in suites. This model is expected to drive growth in oncology and Alzheimer's care.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP revenue of $5.5 billion - $5.65 billion for 2025, up 15.4% YoY. Adjusted EBITDA guidance of $465 million - $475 million reflects 5.2% YoY growth. Adjusted EPS of $1.65 - $1.72, up 10.8% YoY, supported by $50 million in share buybacks.
- **Gross Profit**: $269 million in Q2, up 8% YoY, driven by acute therapy mix and rare drug contributions. Gross margin rate pressured by lower-margin chronic therapies, but gross profit dollars remain strong.
- **Operating Efficiency**: SG&A growth of 10% in Q2 due to M&A and investments in clinical capabilities. Operating expenses are expected to leverage in H2 as infrastructure investments bear fruit.
- **Stelara Impact**: Q2 impact of $20 million, with full-year impact estimated at $60 million - $70 million. Management notes this was fully offset by top-line growth and cost control.

**【Q&A Highlights】**
- **Payer Conversations**: Heightened interest in site-of-care redirection, with payers leveraging Option Care's home/alternate site model to reduce costs. Infusion suites now handle 35% of nursing visits, up from 17% in 2021.
- **Therapeutic Mix**: Acute therapies generate >50% margins, while chronic therapies range 5%-30%. Rare drugs contribute lower margins but drive top-line growth.
- **Tariff Preparedness**: No material 2025 impact expected from tariffs or MFN pricing. Management maintains proactive inventory management and pharma partnerships to mitigate risks.
- **M&A Strategy**: Focused on core expansion and clinical capability enhancement. Recent Intramed acquisition supports advanced practitioner model scale.
- **2026 Outlook**: Acute growth may moderate in Q4 2025 due to 2024 competitive exits, but long-term confidence in 3-5% market growth. Chronic therapies expected to grow 10-15% YoY driven by new launches.


Option Care Health, Inc. (OPCH) Q2 2025 Earnings Call Transcript

- **Revenue Surge**: 16% YoY growth, with acute therapies up mid-teens and chronic therapies high-teens, fueled by improved supply chain and national scale execution.
- **AI-Driven Efficiency**: AI and RPA reduce bad debt, with Palantir integration cutting patient onboarding time by 30%.
- **Acquisition Payoff**: Intramed Plus adds 750 chairs, driving 1/3 of Q1 nursing visits in centers, with seamless integration.
- **Financial Resilience**: $111.8M EBITDA despite $5M STELARA impact, with guidance raised to $455-470M despite tariff uncertainty.
- **Share Buyback**: $100M repurchased in Q1, with $400M remaining under buyback plan.

**【CEO Summary Section】**
- **Revenue Growth**: Q1 2025 revenue grew 16% YoY, driven by mid-teens growth in acute therapies and high-teens growth in chronic therapies. Acute therapy expansion benefited from improved IV bag supply and national scale execution.
- **Investments in Technology**: Expanded AI and robotic process automation (RPA) for revenue cycle management, reducing bad debt and improving cash collection. Launched Palantir AI for patient onboarding.
- **Acquisition Integration**: Intramed Plus acquisition added 750 infusion chairs and advanced practitioner models, with seamless integration and on-track financial performance.
- **Tariff Risk Management**: Cross-functional team assessing tariff impacts on medical supplies, with 10% of med supplies sourced from China. Guidance cautious due to macroeconomic uncertainty.

**【CFO Financial Commentary】**
- **Financial Highlights**: Q1 2025 revenue $1.35B (16% YoY), adjusted EBITDA $111.8M (13.7% YoY), adjusted EPS $0.40 (14.3% YoY). Repurchased $100M stock, maintaining strong balance sheet.
- **STELARA Impact**: $5M of $60-70M annual gross profit impact realized in Q1, with remaining impact expected in subsequent quarters. Inventory management mitigated Q1 impact.
- **Guidance Update**: Full-year 2025 EBITDA raised to $455-470M (from $445-470M), reflecting Q1 performance but leaving top end unchanged due to tariff uncertainty.

**【Q&A Key Highlights】**
- **Tariff Dynamics**: 50% of drugs procured directly from manufacturers, with reimbursement reference prices (AWP/ASP) tied to procurement costs. Tariff pass-through risk minimal but under close monitoring.
- **STELARA Outlook**: Biosimilar uptake aligns with expectations, with retained patient census and clinical program strength. $60-70M annual impact remains unchanged.
- **Acute Sustainability**: 16% Q1 acute growth driven by competitive exits and supply chain improvements. Expect mid-single-digit long-term growth but cautious on calendarization.
- **M&A Strategy**: Active in corporate development, prioritizing low-risk, complementary deals like Intramed Plus. $400M remaining buyback authorization.


Option Care Health (OPCH)-29 Apr 25-2025 Q1 Earnings call transcript

- **Q4 2024 Strong Growth**: 19.7% revenue growth, driven by rare therapies and acute recovery. Acquired Intramed Plus, adding $100M revenue and $5M EBITDA in 2025.
- **2025 Outlook**: Despite $60-70M STELARA headwind, expects earnings growth through portfolio diversification. Adjusted EPS guidance of $1.59-1.69 reflects cost efficiency and capital deployment.
- **Operational Excellence**: SG&A as % of revenue down to 12.2%, with cash flow of $323M in 2024. Infusion suites now handle 1/3 of nurse visits, boosting productivity.
- **Strategic Acquisitions**: Intramed Plus acquisition exemplifies accretive M&A strategy, leveraging national scale to enhance local care delivery.
- **Risk Management**: Navigated supply chain challenges and competitive shifts, maintaining resilience through national platform and disciplined capital allocation.

**【CEO Opening Remarks】**
- **Revenue Growth**: Q4 2024 revenue grew 19.7% YoY, driven by balanced performance across the portfolio, with significant contributions from rare and orphan therapies. Acute therapy growth improved to high single digits despite supply chain challenges.
- **Acquisition Update**: Acquired Intramed Plus in late January 2025, expanding the advanced practitioner model to 15 sites. This adds $100 million to 2025 revenue and $5 million to adjusted EBITDA.
- **Network Expansion**: Opened 2 new state-of-the-art compounding pharmacies in NYC and Tampa, enhancing local responsiveness and resilience.
- **2025 Outlook**: Despite a $60-70 million gross profit headwind from STELARA, expects overall earnings growth through portfolio diversification and clinical program strength.

**【CFO Financial Highlights】**
- **Q4 2024 Results**: Adjusted EBITDA of $121.6 million (+8.9% YoY), adjusted EPS of $0.44 (+15.8% YoY). Full-year cash flow of $323 million, with $250 million used for share buybacks.
- **2025 Guidance**: Revenue $5.3-5.5 billion, adjusted EBITDA $450-470 million, adjusted EPS $1.59-1.69. Includes $60-70 million STELARA impact but maintains growth through portfolio balance.
- **Cost Efficiency**: SG&A as a % of revenue dropped to 12.2%, with full-year spending growth under 4% despite investments in infrastructure.

**【Key Q&A Insights】**
- **Acute Therapy Dynamics**: Supply chain improvements resolved IV solution shortages, enabling normal patient onboarding. Competitive shifts (e.g., competitors exiting) created opportunities, but chronic therapies (75% of revenue) provide stability.
- **STELARA Management**: Maintaining clinical support for complex patients despite margin decline. Biosimilar impact in 2025 is minimal, but long-term dynamics will evolve.
- **M&A Strategy**: Focused on accretive tuck-in acquisitions (e.g., Intramed Plus at mid-teens multiple). Integration playbook leverages procurement, tech, and clinical tools to drive synergies.
- **Infusion Suites Utilization**: 1/3 of nurse visits now occur in suites, with 20%+ productivity gains. Advanced practitioner model expansion (15 sites) targets complex therapies and Medicare fee-for-service access.
- **Payer Relationships**: Medicare Advantage plans increasingly prioritize lower-cost settings, aligning with Option Care's home infusion model. Conversations focus on total cost of care and value-based contracts.


OPCH

OPCH fundamentals

Earnings Call

You can ask Aime